Introduction
Cytokines protect the host against infectious pathogens and the development and survival of neoplastic cells. The interferon (IFN) family of cytokines stimulates antiviral, antitumor, and immunoregulatory activities. Using the Janus tyrosine kinases (JAK)-Signal Transducing Activator of Transcription (STAT) pathway (Darnell et al., 1994) , IFNs induce the expression of a number of cellular genes, which mediate their diverse actions. A central role for IFNs in neoplastic cell growth suppression was highlighted by observations such as an increased incidence of carcinogen-induced tumors in the IFN-g receptor 7/7 and STAT1 7/7 mice, and a failure to reject the STAT1 null tumors by the immune system (Kaplan et al., 1998) . Some IFNregulated factors such as IRF-1 and ICSBP (IFNconsensus sequence binding protein), act as tumor growth suppressors and mutations in these genes have been implicated in the development of myeloid leukemias (Holtschke et al., 1996; Willman et al., 1993) . Since STAT1 and IRFs are transcription factors, their growth suppressive eects are ultimately dependent on the downstream gene products induced by them. Among these two IFN induced antiviral enzymes, protein kinase R (PKR) and Ribonuclease L (RNaseL) have been implicated in stress-induced and spontaneous apoptosis (Balachandran et al., 1998; Der et al., 1997; Zhou et al., 1997) . However, PKR and RNaseL independent growth suppressive actions of IFNs have also been described (Kalvakolanu, 2000; Levy-Strumpf and Kimchi, 1998) . IFNs also activate growth suppressive proteins such as pRb (Resnitzky et al., 1992) and down regulate c-myc, E2F and cyclin D3 in certain lymphoblastoid tumor cell lines (Raveh et al., 1996; Tiefenbrun et al., 1996) . Although IFNs are are eective in the therapy of certain leukemias, they are marginally active in the therapy of solid tumors (Gutterman, 1994) . To overcome this drawback a number of combination therapies have been developed. Among these, the combination of IFNs with retinoids is highly eective against several tumors (Moore et al., 1994) .
Retinoids are vitamin A derivatives, which induce the expression of genes involved in dierentiation, growth control and metabolism using speci®c nuclear receptors (Mangelsdorf and Evans, 1995) . In vitamin A deprived animals, high incidence of a number of carcinomas and leukemias (Love and Gudas, 1994) and an abnormal rise in myelopoiesis owing to a loss of spontaneous apoptosis (Kuwata et al., 2000) were noted. All trans Retinoic Acid (RA), a prototypic retinoid, can either suppress or reverse these eects in vivo. RA inhibits the growth of certain neuroblastomas, promyelocytic leukemias, and teratocarcinomas in vitro (Love and Gudas, 1994) . Two structurally similar but genetically distinct transcription factors, the retinoic acid receptor (RAR) and the retinoid X receptor (RXR) induce the expression of genes involved in growth suppression (Glass et al., 1997) . However, the nature of these retinoid-regulated inhibitors of cell growth is unknown. A perplexing number of RAR and RXR isoforms present in mammalian cells (Mangelsdorf and Evans, 1995) seem to mediate this complex process. Based on this, several synthetic and natural retinoids that can dierentially activate these receptors have been identi®ed. The growth suppressive eects of synthetic retinoids are mediated by a RAR ± RXR dependent and independent manner (Liu et al., 1996; Lotan, 1996) . Induction of caspase-dependent cleavage of ubiquitous transcription factor Sp1 and cell death by certain synthetic retinoids occurs independent of transcription (Piedra®ta and Pfahl, 1997) . Other synthetic retinoids induce cell death by a p53 dependent or caspase dependent manner (Sun et al., 2000) . Some retinoids activate translocation of orphan nuclear receptor TR3 from nucleus to the mitochondrion, and the consequent release of cytochrome c to induce apoptosis (Li et al., 2000) .
Although IFN and RA use dierent signaling pathways, a cross talk between their growth suppressive pathways exists. PML ± RARa, a mutant chimeric retinoic acid receptor found in certain acute promyelocytic leukemias responds to RA. Interestingly, this mutant receptor is induced by IFNs and has been reported to participate in the anticellular action of IFN-a (Chelbi-Alix et al., 1998; NasonBurchenal et al., 1996) . PML forms a nuclear body consisting of several IFN-inducible gene products Gongora et al., 1997) . PML is induced by IFNs and its promoter contains STAT1 binding sites (Pelicano et al., 1997) . In certain IFNresistant cells, RA induces STAT1 levels resulting in an enhancement of IFN-responses (Gianni et al., 1997; Kolla et al., 1997; Matikainen et al., 1997) . RA has also been shown to induce some ISGs directly (Pelicano et al., 1997) . Indeed, several clinical and experimental studies have shown that the IFN/RA combination is a more potent inhibitor of cell growth than either drug alone (Lindner et al., 1997; Moore et al., 1994) .
We have shown earlier that the IFN/RA combination, but not the single agents, causes cell death in vitro and suppresses tumor growth in vivo (Lindner et al., 1997) . Furthermore, no detectable activation of IFNstimulated PKR or RNaseL and no change in p53 levels, and pRb phosphorylation status occurred under these conditions (Hofmann et al., 1998) . These data suggested the existence of novel IFN/RA-regulated mechanisms of cell death. To identify the genes responsible for cell death and de®ne their mechanism of action, we employed an antisense technical knockout approach (Deiss and Kimchi, 1991) . In this approach speci®c death-associated genes are identi®ed by their ability to confer a growth advantage to cells in the presence of death inducers, when expressed in an antisense orientation. This resulted in the identi®cation of several Genes associated with Retinoid-IFN induced Mortality (GRIM) (Hofmann et al., 1998) . One of the GRIMs, GRIM-12, was identical to human thioredoxin reductase (TR), an intracellular redox regulatory enzyme (Hofmann et al., 1998) . In this study, we show that thioredoxin 1 (Trx1), the downstream substrate of TR, mediates some of the death functions. The activation of certain members of the caspase family is regulated by IFN/RA combination through thioredoxin. We show that the wildtype, but not redox inactive Trx1 mutant promotes cell death by stimulating caspase-8 activation.
Results

Role of Trx in the IFN/RA induced cell death
Our previous studies have shown that thioredoxin reductase is critical for cell death to occur in human breast carcinoma cells, following IFN-b/RA treatment. Since mammalian TR can reduce a variety of substrates (Arner and Holmgren, 2000) , we have examined the role of its well-known substrate, Trx1, in cell death regulation. Although a recent member of this family, Trx2, has been described (Spyrou et al., 1997) this study will primarily focus on the wellcharacterized substrate Trx1. Therefore, MCF-7 cells were transfected with mammalian episomal vector pTKO1 or the same vector carrying the human Trx1gene in an antisense orientation. Following this cells were selected with Hygromycin B in the presence or absence of human IFN-b (500 U/ml) and RA for 3 weeks. Cells transfected with pTKO1 vector perished following IFN/RA treatment as evidence by a lack of colony formation ( Figure 1a) . In contrast, a signi®cant number of cell colonies survived in the pTKO1-Trx transfected plates under similar conditions. The lack of colonies in pTKO1 transfected plates was not due to toxic eect of the transfection protocol, because a number of colonies have survived in the presence of Hygromycin alone. Interestingly, a fraction of pTKO1-Trx transfected cells survived the toxic eect of IFN-b/ RA. Thus, antisense Trx oers a partial protection against cell death.
The cell protective function of antisense Trx was also con®rmed in two independent assays. These are: (1) a colorimetric growth assay that quanti®es cell number and (2) annexin-V binding assay, which quanti®es apoptotic cells. Equal numbers of cells were plated and exposed to IFN/RA combination for 7 days. Cell growth was compared to the untreated controls for each cell line. IFN/RA treatment of pTKO1 transfected cells caused cell death as measured in the colorimetric assay. Under the same conditions, cells expressing the antisense Trx1 were resistant to cell death (Figure 1b) . Similarly, signi®cantly higher annexin-V positive cells were observed in pTKO1-transfected cultures than in the antisense Trx transfected cells (Figure 1c ). These data suggest that Trx1 plays a role in IFN/RA induced cell death.
Inhibition of cell death was due to down regulation of Trx levels
We next determined whether the survival was due to the expression and the consequent downregulation of cellular Trx levels. Total RNA was prepared from IFN/RA treated MCF-7 cells transfected with pTKO1 and antisense-Trx1 and analysed by Northern blotting. These blots were probed with 32 Plabeled human Trx1 cDNA. As expected a mRNA corresponding to the endogenous Trx1 (E) was detected in both cell types (Figure 2a) . However, an additional band corresponding to the antisense Trx mRNA was found only pTKO1-Trx transfected cells. This mRNA moves to a higher position on the gel (indicated by a ®lled triangle) than the endgenous mRNA due to the fact that vector derived untranslated sequence is added to the 3' of the antisense gene.
To determine whether antisense mRNA expression caused a depletion of Trx protein, Western blotting was performed using human Trx1 speci®c antibodies. Equal amounts of cell extracts from cells described above were used in this experiment. As shown in Figure 2b , although the Trx protein was detected in both cases, its levels were signi®cantly suppressed (7 ± 8-fold) in the pTKO1-Trx cells compared to the vector transfected cells. These blots were also probed with a monoclonal antibody against actin protein to ensure the presence of comparable amounts of protein in both the lanes.
Trx is involved in the IFN/RA induced death pathway
To further demonstrate the role for Trx in IFN/RA induced cell death MCF-7 cells were stably transfected with the expression vectors carrying wildtype or mutant Trx. The mutant bore serine residues in the place of critical cysteines at positions 32 and 35. Two (a) MCF-7 cells were transfected with episomal vector pTKO1 or the same vector carrying the Trx1 cDNA in an antisense orientation were selected for 2 weeks with Hygromycin B (100 mg/ml), in the absence (7) or presence (+) of human IFN-b (500 U/ml) and RA (1 mM). The plates were then ®xed, stained with Sulforhodamine B prior to photography. In (b) the same cells were used in a colorimetric growth assay (see Materials and methods) for quantifying the dierences in death sensitivities of the cell lines expressing vector and antisense Trx1. Cells were treated with IFN and RA as described above for 5 days. Absorbance values for 0 and 100% growth in this experiment are 0.162 and 0.602, respectively. Each data point represents mean+s.e. of 12 replicates. (c) Cells treated with IFN/RA were stained with annexin-V as described under Materials and methods. The percentage of annexin-V positive cells was quanti®ed using FACS analysis. Each bar represents mean+s.e. of triplicates sets of plates were set up in each case. In one case, the number of G418 resistant colonies formed (Figure 3a ) after transfection was determined by staining the transfected plates with Sulforhodamine B and in the other, the resultant colonies were pooled and used in the experiments. Transfection of expression vector alone in to MCF-7 cells resulted in the formation of *150 G418-resistant colonies (bar 1). A signi®cantly reduced number of colonies (*33% fewer) formed upon transfection of cells with wildtype Trx1 (bar 2). In contrast, plates transfected with the mutant yielded a higher number of colonies (35% more) than in the control (bar 3 in Figure 3a ). These data suggest that overexpression of wildtype Trx is cytotoxic while the mutant is protective. Cells expressing wildtype Trx1, survived after selection with G418, grew slower than those expressing either the empty vector or mutant Trx (Figure 3b ). These data indicate that expression of moderate levels of Trx1 impedes cell growth.
We next examined whether these dierential eects on cell growth were due to the expression of wildtype and mutant Trx1. Total RNA was extracted from cell lines stably transfected with Trx1 or its mutant and a comparable amount of RNA was employed in Northern blot analysis. These blots were probed with human Trx1 probe. Cells transfected with the mutant Trx had a 12-fold high level of Trx mRNA compared to the vector transfected ones (Figure 3c , compare bars 1 and 2). In contrast a sixfold more Trx mRNA was found in the wildtype Trx transfected cells than those with the vector alone. Similarly, we also examined the expression of Trx protein by Western blotting. The wildtype and mutant Trx expressing cells had three-and sevenfold more Trx1 protein, respectively ( Figure 3d ). The lower level of wildtype Trx protein in transfected cells suggests that a higher level of this protein is cytotoxic. This suggestion is also consistent with the observation that mutant Trx1 is expressed at a higher level than the wildtype Trx1. These cells grew better than those overexpressing wildtype Trx1 gene ( Figure  3a ,b).
Overexpression of Trx promotes cell death
Based on the above results we determined whether cells expressing wildtype Trx1 were more sensitive to the death-inductive eects of IFN/RA combination than those expressing the vector or mutant Trx1. In the ®rst set, an equal number of cells expressing the wildtype or the mutant Trx1 were exposed to the IFN-b/RA combination for 2 weeks. The cell colonies were visualized after ®xation and staining with Sulforhodamine B (Figure 4a ). As expected wildtype Trx expressing cells were killed by the IFN/RA. Conversely, the cells carrying mutant Trx were resistant to cell death. However, prolonged treatment (4 weeks) or higher concentration of IFN/RA (2000 U/ml and 1 mM) caused cell death in mutant Trx1 expressing cells (data not shown). These observations suggest that Trx1 is one of the players in this death pathway and the IFN/RA combination can induce cell death in a Trx1-independent manner, depending on the strength of the death signal.
Although the above data indicated the sensitivity and resistance of the cells expressing wildtype and mutant Trx, respectively, they did not reveal the relative dierences between the death sensitivities of wildtype and vector expressing cells. Therefore, MCF-7 cells stably transfected with the vector, wildtype, and mutant, were exposed to IFN/RA combination and cell growth was monitored in short term assays. Cell growth was measured on two dierent time points after IFN/RA treatment and the data were expressed as a per cent of the untreated control. Although both the vector and wildtype Trx1 expressing cells were inhibited by IFN/RA the latter were threefold more sensitive than the former in a 4-day growth assay ) expressing various plasmids were selected with G418 (1 mg/ml), IFN-b (500 U/ml) and RA (1 mM) for 2 weeks and then with G418 alone for 1 week. Colonies surviving on the plates were ®xed and stained with sulforhodamine B as described above. (b), (c) Cell death induction by the IFN-b/RA combination. Cell growth was measured using sulforhodamine B as described in Materials and methods (Skehan et al., 1990) . Each data point represents mean+s.e. of six replicates. The absorbance value for 0% growth is 0.168, 0. (Figure 4b ), as measured by the amount of growth occurred. Importantly, the cells transfected with wildtype Trx1 were twofold more sensitive to IFN/RA induced death (negative values on the y-axis) compared to the vector transfected ones as revealed in a 7-day assay. In contrast, cells transfected with the mutant did not die after IFN/RA treatment (Figure 4c ). These observations were also con®rmed by annexin-V staining (Figure 4d) . In contrast to the mutant transfected cells, a robust death activation occurred in the vector and wildtype Trx1 transfected cells with IFN/RA treatment. The wildtype Trx1 expressing cultures bound 2 ± 3-fold more annexin-V than the vector expressing cells. These data indicate that the mutant Trx1 interferes with IFN/RA-induced apoptosis.
Higher TR activity in the Trx1 transfected cells
We next examined whether the hypersensitivity of cells to IFN/RA induced death activation was due to an enhancement of TR activity. An equal quantity of protein from cells expressing the vector, wildtype, and mutant Trx1 was used for determining the TR activity ( Figure 5a ). The wildtype Trx1 expressing cells had twofold more TR activity than the vector expressing ones. In contrast, the mutant expressing cells had a signi®cantly lower enzymatic activity. In this experiment no exogenous Trx was added to the lysates. Any activity seen is due to endogenous Trx. Thus, an increase in enzymatic activity corresponds to cellular hypersensitivity to IFN/RA induced death.
It can be argued that the increase and decrease in the TR activities of the wildtype and mutant Trx1 expressing cells, respectively, is due to dierential catalytic activities of TR in these cells. Therefore, we have determined the relative activities using exogenous Trx as substrate. In this experiment the basal absorbance values observed in the absence of exogenous Trx was subtracted from the experimental values. As shown in Figure 5b , no dierences in the catalytic activity of TR from the vector, wildtype and mutant Trx1 transfected cells were noted.
Trx1 activates cell death
Since the above experiments indicated that overexpression of Trx1 causes reduction in the number of G418 resistant colonies formed (Figure 3 ) and indirectly indicated a loss of cell viability, the eect of Trx1 overexpression on cell survival was determined using a transient assay. MCF-7 cells were transfected with CMV-b-galactosidase and the expression vectors for wildtype Trx1 or the mutant. Three days after transfection, cells were ®xed and stained with X-gal to determine the percentage of dead cells. Blue colored cells with a normal epithelial morphology were considered live and those with a rounded appearance were considered dead. The percentage of cell death was determined from the ratio of dead blue cells to the total blue cells. As shown in Figure 6 , wildtype but not mutant Trx1 caused a dose dependent cell death. Vector alone did not cause signi®cant cell death. Although the percentage of cell death was smaller it was distinctly dierent from the controls. At 2 mg, wildtype Trx1 caused a sevenfold increase in cell death compared to the vector transfected cells (bar 1), but not with the mutant. Similar data was obtained in T47D breast carcinoma cells (data not presented). Thus, Trx1, when overexpressed, activates cell death in dierent tumor cell lines. In (a), the basal TR activity using endogenous Trx was measured using 50 mg of total cell extract. In (b), the catalytic activity of TR in the extracts of various cell lines was measured using exogenous Trx as substrate. In each case background enzymatic activity (in the absence of exogenous Trx) was measured and subtracted from the experimental values. In this experiment 20 mg of cell extract was used. Each bar represents mean+s.e. of triplicates. The absorbance was in the linear range compared to control enzyme, TR 
IFN/RA induced cell death is dependent on caspase activation
Since most cell death signals culminate in caspase activation and our recent studies indicated that caspases are activated during IFN/RA regulated cell death, we next examined whether the Trx1 induced cell death was dependent on caspases. For this purpose, a chemical caspase inhibitor z-VAD-fmk and a biological caspase inhibitor C-FLIP were employed in the subsequent experiments (Figure 7 ). In the ®rst experiment MCF-7 expressing wildtype Trx1 were treated with IFN/RA in the presence and absence of z-VAD-fmk. While cell death was clearly noted in the absence of the inhibitor, it was strongly suppressed in its presence (Figure 7a ). Similar results were obtained with annexin-V binding assays (data not shown). Since z-VAD-fmk is a general caspase inhibitor, we have examined the in¯uence of C-FLIP (Thome et al., 1997) and a catalytically inactive caspase-8 mutant on Trx1 induced cell death. C-FLIP suppresses death receptor-induced apoptosis by interfering with caspase-8 functions. It is a structural homolog of caspase-8 but lacks the critical cysteine at the active site. MCF-7 cells were transiently transfected with a CMV-b-galactosidase expression vector and wildtype Trx1. Along with these plasmids the expression vector carrying a catalytically inactive caspase-8 mutant (C?A) or C-FLIP was also transfected. The percentage of death was determined following staining with X-gal (Figure 7b ). Transfection of Trx1 caused 22% death. However, co-expression of the caspase-8 mutant signi®cantly suppressed such cell death. Expression of caspase-8 mutant alone did not cause any signi®cant increases in death compared to the vector transfected control. In a similar manner, C-FLIP also inhibited Trx1 activated cell death. These data suggest that Trx1 induced cell death is dependent on caspases, in particular caspase-8.
Trx1 modulates caspase-8 induced cell death
Because Trx1-activated cell death was suppressed in the presence of caspase-8 mutant or C-FLIP, it was of interest to examine whether Trx1 targets speci®c caspases during induction of cell death. We have chosen two speci®c caspases, caspase-8, and caspase-3 for this study. A number of studies have been shown that these enzymes participate in the initial and terminal phases of cell death, respectively, in response to extracellular death activators. Cells were transfected with RSV-b-galactosidase and caspase-8 expression vectors. Along with these either wildtype Trx1 or the mutant expression vector was cotransfected. Thirty-six hours later cells were stained with X-gal and the percent of cell death was determined as described in the Methods section. As shown in Figure 8a , transfection of wildtype Trx1 caused a signi®cant cell death, as determined by the number of dead cells expressing bgalactosidase. In this experiment, we employed a suboptimal concentration of wildtype Trx1 to distinguish its stimulatory eect on caspase-8 induced death. Caspase-8 overexpression itself caused cell death. Cotransfection of vector alone did not augment caspase-8 induced cell death. However, cotransfection of expression vector for wildtype Trx1 augmented cell death signi®cantly higher than either plasmid alone, indicating a synergistic eect. In contrast, the mutant Tyx1 strongly interfered with the death inductive eect of caspase-8.
The IFN/RA inducible cell death did not involve internucleosomal DNA fragmentation in MCF-7 cells (Hofmann et al., 1998) . MCF-7 cells do not express endogenous casapse-3 protein due to a deletion of 47-nucleotides in the ®rst exon of caspase-3 gene (Janicke et al., 1998) . Although, IFN/RA combination does not Figure 7 Eect of caspase inhibitors on IFN/RA induced death. SRB binding assay was performed with cells exposed to IFN-b (500 U/ml), RA (1 mM) or their combination for 7 days. MCF-7 cells expressing wildtype Trx1 were pre-treated with z-VAD-fmk (10 mM) and then with IFN/RA combination. The 0 and 100% growth values in this experiment are: 0.157 and 0.913, respectively. Panel B Inhibition of Trx1 induced cell death by a mutant Casapse-8 or C-FLIP. MCF-7 cells were transfected with a b-galactosidase reporter (1 mg) of Trx1 (2 mg). Along with these 1 mg of either a mutant caspase-8 or C-FLIP was co-transfected. Percentage of death was calculated as described above. pcDNA 3.1 was used to normalize the total amount of DNA transfected Oncogene Cell death regulation by a redox regulatory factor X Ma et al require caspase-3 for inducing cell death in MCF-7 cells, it may be required in other cell types for death to occur in response to this combination. Since MCF-7 cells lack the endogenous capsase-3, they oer a good model to test the eect of Trx1 on the co-transfected casapse-3. Therefore, MCF-7 cells were transfected with a caspase-3 expression vector along with the RSVb-galactosidase reporter plasmid. In addition to these plasmids either wildtype Trx1 or the mutant was coexpressed to examine their in¯uence on casapse-3 induced cell death ( Figure 8b ). As anticipated caspase-3 expression caused an increase in cell death and expression vector alone had no signi®cant eect on it. Although wildtype Trx1 marginally increased caspase-3-dependent cell death, the mutant did not inhibit the caspase-3 induced death. The higher amount of caspase-3 induced death in this case may be due to the fact that caspase-3 is a terminal enzyme in the death pathway and it can potentially activate mid-level caspases, such as caspase-9 through an ampli®cation of caspase cascades (Green and Reed, 1998; Gross et al., 1999) .
Activation of caspase-8 during IFN/RA induced cell death
To directly test whether caspases-8 was activated during IFN/RA induced cell death, Western blot analyses were performed using speci®c antibodies. MCF-7 cells expressing various Trx1 mutants were treated with the IFN/RA combination for 5 days. Cell lysates were prepared and used in Western blot analyses. As shown in Figure 9 , Caspase-8 was activated in vector-transfected MCF-7 cells upon IFN/RA treatment. In the cells expressing wildtype Trx1, a higher magnitude of caspase-8 activation occurred as evidenced by the conversion of procaspase-8 into active form. In contrast, no activation of caspase-8 occurred in cells expressing the mutant Trx1. We also determined the cleavage of poly ADP ribose polymerase (PARP), a marker of caspasemediated apoptosis in these cells. IFN/RA combination induced the cleavage of PARP in the vector-transfected cells. A similar but enhanced cleavage of PARP was noted in cells expressing wildtype Trx1. PARP cleavage was not detected in cells expressing mutant Trx1 ( Figure  9 , bottom panel).
Discussion
Several anti-oxidant mechanisms govern the survival of mammalian cells. These include superoxide dismutase, catalase, glutathione, thioredoxin, selenoproteins and the thiol-speci®c antioxidant (Berlett and Stadtman, 1997; Nakamura et al., 1997) . Some of these protect the cells, while the others suppress abnormal cell growth. Thioredoxin (Trx) participates in a wide-array of activities including cell growth, transcriptional and immune functions (Arner and Holmgren, 2000) . Thioredoxins are ubiquitous proteins that mediate not only redox but also non-redox functions (Arner and Holmgren, 2000) . The conserved cysteine moieties of Cell lysates were prepared and Western blot analyses, with the indicated antibodies, were performed using (100 mg) of protein from each sample. Cleavage products were indicated with arrows the sequence, Cys-Gly-Pro-Cys, are necessary for the redox function of thioredoxin (Arner and Holmgren, 2000) . Several thioredoxins or thioredoxin-like proteins exist in mammalian cells (Kurooka et al., 1997; Lee et al., 1998b; Spyrou et al., 1997) , whose individual physiologic roles have not been clearly understood. The most-well characterized member of these thioredoxins, Trx1, is critical for mammalian development because a homozygous deletion of this gene causes embryonic lethality in mice (Matsui et al., 1996) . Trx also plays a regulatory role in yeast, Drosophila and Xenopus cell division. The Trx homolog of Drosophila, deadhead, is essential for female meiosis and early embryonic development (Salz et al., 1994) , but not for DNA synthesis in vivo (Pellicena-Palle et al., 1997). Thioredoxin inhibits DNA synthesis in the fertilized Xenopus eggs (Hartman et al., 1993) . In yeast lacking the Trx gene an increase in the frequency of mitotic cell cycle occurs (Muller, 1991) . Loss of TR gene relieves p53-dependent growth suppression in yeast (Casso and Beach, 1996; Pearson and Merrill, 1998) . While these studies highlighted the essential role of thiodredoxin system in cell growth suppression, the exact targets TR:Trx aects have not been de®ned clearly. Since these enzymes modify their substrates in an extremely transient manner and no stable prosthetic groups are involved in this process (Arner and Holmgren, 2000) , it has been dicult to de®ne their targets. Therefore, application of genetic methods will be useful in identifying the downstream eectors.
The redox status of Trx is modi®ed by an upstream regulatory enzyme thioredoxin reductase (TR). This gene is now known as TR1 and is expressed ubiquitously in the mammalian tissues (Arner and Holmgren, 2000) . Recently, two other TR homologs TR2 and TR3 have been identi®ed using database searches or by biochemical puri®cation Sun et al., 1999) . The latter two are expressed in a tissue and organelle speci®c manner. The speci®c roles of these new members of TR family enzymes are unclear at this stage. Mammalian TR has broader substrate speci®city, unlike its prokaryotic homologs (Arner and Holmgren, 2000) . For example, it can reduce unrelated compounds such as selenite, alloxan, 5,5'-dithiobis(2-nitorbenzoic acid), in addition to Trx. It is likely that each TR exhibits a narrow-substrate speci®city and acts in a localized manner.
Using the antisense knockout approach we have shown earlier that TR1 is critical for the cell death controlled by IFN/RA and IFN/Tamoxifen combination (Hofmann et al., 1998; Lindner et al., 2000) . In this approach the death associated genes are identi®ed based on functional inactivation (Deiss and Kimchi, 1991; Hofmann et al., 1998) . Over expression of TR1 led to a signi®cant decrease in the viable cell colony formation. Although some cells expressing moderate levels of TR1 were viable, they grew slower than the vector-transfected cells and were hypersensitive to death induction by IFN/RA (Hofmann et al., 1998) . That TR1 exerts growth suppressive functions via apoptosis in the presence of exogenous ligands is also consistent with other studies which showed that Trx1, when inactivated in a similar manner, suppresses IFN-g induced cell death (Deiss and Kimchi, 1991) , and certain tumor cells that hyper produce Trx grow poorly (Rubartelli et al., 1995) . Although overexpression of Trx1 in clonal isolates of certain transformed cells promotes growth, the majority of the cells overexpressing Trx1 did not survive (Gallegos et al., 1996) . Lastly, RA induces the transcription of the Trx1 gene and enforced expression of Trx1 causes cell death in lung epithelial cells (SPM Reddy and R Wu, unpublished data). Collectively these data indicate that TR1:Trx1 can regulate cell death in mammalian cells. In contrast, some studies have shown that certain HTLV-transformed lymphocytes secrete Trx in high amounts and grow rapidly indicating a cytokine-like function for this protein (Tagaya et al., 1989) . Other studies have shown that Trx inhibits the apoptotic activity of ASK1/MKKK5 (Saitoh et al., 1998) . In this case Trx appears to be functioning as a chaperone that controls the apoptotic activity (Liu et al., 2000) , by preventing the oxidation of ASK1 and the consequent loss of its activity.
In this study we have shown that antisense expression and a redox-inactive Trx1 mutant clearly interfered with cell death. Conversely, over expression of wildtype Trx1 promoted cell death. These results are in contrast to other studies, which reported a growthpromoting role for Trx1. These contrasting observations raise the question: how can a growth-promoting factor regulate diverse eects? The reasons for these dierences could be manifold: (1), unlike the previous studies which employed supra-physiologically overexpressed wildtype Trx1, we show that down regulation of physiological Trx1 levels promotes cell death; (2), there was no selection pressure on the cells in the previous studies; (3), the growth promoting eect of Trx1 was cell type dependent. For example, while secreted Trx was growth promoting in HTLV-transformed cells (Tagaya et al., 1989) , it was inhibitory for hepatocellular carcinomas (Rubartelli et al., 1995) . In a similar manner EGF Chin et al., 1997) , oncoprotein c-myc (Evan et al., 1992; Hermeking and Eick, 1994; Wagner et al., 1994) and transcription factor E2F (Field et al., 1996; Pierce et al., 1999) , which promote cell growth, can also induce apoptosis depending on the physiologic status of the cell. Indeed, E2F has been shown to act as a transcriptional inhibitor in the presence of RA (Lee et al., 1998a) . Additionally, p202, an IFN-induced protein suppresses the DNA binding and transcriptional activity of E2F by a direct interaction (Choubey et al., 1996) . Thus, Trx can participate in both growth stimulatory and suppressive functions, depending on the physiologic context and in¯uence of extracellular agents.
Cell death in multicellular organisms is controlled by a`central machinery' consisting of caspases and BCL proteins (Green and Reed, 1998; Gross et al., 1999) . It is clear that a number of disparate signals feed into this central regulatory unit during death activation. This suggests the existence of a signal speci®c dedicated switch(es) that turns on this machinery. We show here that one such switch, Trx1, targets caspase-8 during cell death. Evidence presented in this study suggests this property of Trx1: (1) The post-translational modi®cations of death machinery constituents by pro-and anti-death signals in part could account for its regulation. For example, phosphorylation of caspase-9 inhibits its biological activity (Cardone et al., 1998) . Phosphorylation of BAD, a member of BCL family, by Akt and Protein kinase A inhibits its death promoting activity (Datta et al., 1997; Harada et al., 1999; Kennedy et al., 1999) . Recently, N-myristoylation of proapoptotic protein BID has been shown to permit its docking to the mitochondrial membranes and cell death (Zha et al., 2000) . Little is known about other potential posttranslational mechanisms of caspase regulation. One post-translational mechanism that can modulate caspase activity is their catalytic site. The cysteine residue of the active site is critical for these enzymes to execute cells in response to exogenous death signals (Green and Reed, 1998; Gross et al., 1999) . Indeed, a cysteine ? alanine (C?A) mutant of caspase-8 blocked cell death (Figure 7 ). Data obtained with a limited number of caspases used in this study show that caspase-8, but not caspase-3, is selectively activated by Trx1 (Figures  8) . Although, a recent study has shown that caspase-3 activity can be restored upon incubation with Trx1 (Ueda et al., 1998) , a mutant Trx1 was unable to inhibit caspase-3 function in our study. Interestingly, a mutant Trx1 lacking the cysteine residues was unable to inhibit caspase-3. These data suggest that substrates other than Trx1 maintain the redox state caspase-3 in vivo. The dierential eect of Trx1 on caspases may also be due to regulation of caspase activities by its modulator TR in a localized manner. Consistent with our studies evidence for redox regulation of caspase functions has been recently reported. For example, nitric oxide-mediated oxidation and S-nitrosylation of active site cysteine have been implicated in inhibition of caspase-3 activity (Lipton, 1999; Mohr et al., 1997) . Depletion of cellular glutathione levels enhances the apoptotic eect of TNF-a in certain hepatoma cells (Pierce et al., 2000) . Treatment of cells with reducing agents augmented Fas-induced cell death and enhanced caspase-3 activity (Sen et al., 1999) . Furthermore, a number of redox enzymes have been identi®ed as potent mediators of p53-induced death (Polyak et al., 1997) . These data highlight the importance of redox control in cell death. More importantly, Trx1 now provides a link between death machinery and IFNs.
Materials and methods
Reagents
Restriction and DNA modifying enzymes (NE Biolabs); G418 Sulfate, IPTG and Lipofectamine plus (Life Technologies); nitrocellulose membranes, ECL reagents and horseradish peroxidase coupled to anti-rabbit or anti mouse antibodies (Amersham Pharmacia Inc); human IFN-b ser (Berlex Inc.), mouse monoclonal antibodies against actin (Sigma Inc.) and thioredoxin (Serotec Inc.) and rabbit polyclonal antibodies against caspase-8; polyADP ribose polymerase (Santa Cruz Biotech Inc.) were employed in these studies. Fresh stocks of all-trans retinoic acid (Sigma) were prepared in ethanol and added to cultures under subdued light.
Cell culture
MCF-7 cells were cultured in phenol red free EMEM supplemented with 5% charcoal stripped fetal bovine serum (CSFBS) and 10 711 M estradiol during treatment with IFN-b and all trans retinoic acid (RA). Cells were grown in phenol red free media 24 h before treatments were initiated.
Plasmids
Episomal vector pTKO1 contains the human thioredoxin cDNA in antisense orientation, under the control of an IFNstimulated promoter (Deiss and Kimchi, 1991) . Mammalian expression vectors carrying caspase-8 and caspase-3 and the corresponding mutants were provided by Emad Alnemri, Thomas Jeerson University, Philadelphia, USA (Alnemri et al., 1995) . The wildtype and redox inactive mutant of Trx1 cloned in the mammalian expression vector pDSRa were described elsewhere (Hirota et al., 1997) . In the mutant Trx1 the cysteine residues at positions 32 and 35 were substituted with serines.
Cell growth assay
Cells (2000/well) were seeded into 96-well plates. Various inhibitory agents were added and growth was monitored using a colorimetric assay, which quanti®es cell numbers (Skehan et al., 1990) . Each group of treatments had eight replicates. Cells were ®xed with trichloroacetic acid (®nal concentration 10%) at 48C for 1 h at the end of the experiment and stained with 0.4% Sulforhodamine B (Sigma). The bound dye was eluted with 100 ml of Tris-HCl (pH 10.5) and the absorbance was monitored at 570 nm. One plate was ®xed with TCA, 10 h after plating the cells. Absorbance obtained with this plate was considered as 0% growth. Absorbance obtained with untreated cells was considered as 100% growth. An increase and decrease of A 570 values in the experimental wells relative to the 0% value indicates cell growth and death, respectively. When plotted as a percentage of untreated control growth and death values appear on the positive and negative scales of the Y-axis, respectively.
Death assays
Cell death was also determined using an alternate method, the Annexin-V binding assays. Following treatment with the indicated agents, cells were stained using a commercially available kit (Trevigen Inc) per manufacturer's recommendation. Cells were incubated with FITC tagged Annexin-V and propidium iodide. FITC-stained cells were considered as apoptotic and were quanti®ed using Becton-Dickinson uorescence activated cell sorter. Annexin-V positive cells (dead) were scored and expressed as a percentage of total number of cells.
Transient transfection assays
Cell death was also monitored in a transient transfection assay. Since the transfection eciency is only around 20%, it is important to score for the transfected cells. Therefore, a bgalactosidase reporter gene driven by the enhancers of either Rous Sarcoma Viral (RSV) long terminal repeat or the Cytomegalovirus (CMV) was co-transfected along with the eector plasmids. This plasmid permits the detection of transfected cells after staining with X-gal. Brie¯y, cells were transfected with the indicated plasmids (*1 mg) using the Lipofectamine plus reagent. Wherever multiple plasmids were transfected, total amount of DNA transfected was kept to a maximum of 2 ± 4 mg, depending on the experiment. At the end of the experiment they were stained with a commercially available in situ b-galactosidase detection kit containing X-gal (Stratagene Inc) and the number of cells stained blue was determined microscopically. Cells with¯at attached epithelial morphology were considered alive and those with a rounded and detached appearance were considered dead. Multiple ®elds were scanned and a total of 300 ± 400 cells were counted to obtain statistically signi®cant numbers.
Enzymatic assay
Thioredoxin reductase activity was determined as described (Holmgren and Bjornstedt, 1995) . Cell extracts were prepared after IFN/RA treatment by freeze-thaw lysis. Twenty micrograms of extract was incubated with insulin, NADPH and thioredoxin in 0.2 M HEPES, pH 7.6 for 20 min at 378C. Reactions were terminated after the addition of 6 M guanidinium hydrochloride/0.4 mg/ml dithiobis(2-nitrobenzoic acid) prepared in 0.2 M Tris, pH 8.0. Absorbance at 412 nm was measured. In each case a corresponding control without Trx was used to determine the basal level of TR activity (due to endogenous Trx and NADPH). Where indicated absorbance values obtained from these controls were subtracted from those obtained with the reactions that contained Trx and NADPH. A negative control reaction without cell extracts but with all the reaction components was also employed. Triplicate samples were measured for enzymatic activity. Pure TR was used as a positive control.
Northern and Western blot analyses
Total RNA was extracted and comparable amounts of RNA from each cell line/treatment were separated on a 1% formaldehyde-agarose gel. These blots were probed with 32 P-labeled human Trx1 and glyceraldehyde phosphate 3-dehydrogenase (GAPDH) cDNAs. These blots were exposed to X-ray ®lms to detect the expression. Gene expression was quanti®ed using a Molecular Dynamics phosphorimager.
Equal quantities of cell extracts were separated on 12% SDS ± PAGE and Western blotted onto nylon membranes. Speci®c ®rst antibodies were incubated with the blots after blocking as described in our previous publications (Hofmann et al., 1998) . These blots were washed and incubated with an appropriate second antibody tagged with horseradish peroxidase. Protein bands were visualized using a commercially available enhanced chemiluminisence (ECL) kit (Amersham Inc).
Abbreviations FLIP, FLICE-inhibitory protein; GRIM, Genes associated with Retinoid-IFN induced mortality; IFN, Interferon; JAK, Janus tyrosine kinase; RA, all trans retinoic acid; SRB, Sulforhodamine B; STAT, Signal transducing activator of transcription; TR, thioredoxin reductase; Trx, thioredoxin
